Lonza, a global manufacturing partner to the pharmaceutical, biotech and nutraceutical markets, has extended its collaboration with a major global biopharmaceutical partner for commercial-scale manufacture of ADCs.   The extended agreement will expand the dedicated bioconjugation footprint for the customer through the construction of a new bioconjugation suite at Lonza’s Ibex Biopark in Visp (CH). In addition, Lonza will provide commercial-scale monoclonal antibody (mAb) manufacturing services...